UNSPSC 51453702: Becanthone

This classification denotes an antiparasitic agent with the molecular formula C22H28N2O2S, chemically known as 1-((2-(Ethyl(2-hydroxy-2-methylpropyl)amino)ethyl)amino)-4-methylthioxanthen-9-one but generally known as becanthone, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A6P8OYN3G5. The term becanthone is a United States Adopted Name designation. As of Q4 2014, BECANTHONE remains the US FDA Preferred Term for this commodity. Becanthone bears US NLM identifiers UMLS ID C2698337 and NCI Concept Code C79918.

SMILES: CCN(CCNC1=C2C(=C(C=C1)C)SC3=CC=CC=C3C2=O)CC(C)(C)O.

UNSPSC 51453702 Becanthone, a Commodity code, does not align with the recent state and local solicitations tagged under it. The code nominally identifies a specific pharmaceutical substance, but the recent opportunities reflect purchases of naloxone, medical and first aid supplies, generic pharmaceuticals, and pharmacy benefit program services—none of which are becanthone. The mismatch suggests either a tagging error in the underlying procurement system or that becanthone is procured so infrequently under this code that recent activity does not surface becanthone-specific opportunities.

Recent state and local activity under this code reflects broader pharmaceutical and medical supply procurement across health departments, fire rescue divisions, and cooperative purchasing alliances. Issuing bodies include Seminole County, Florida (health initiatives); the City of Tampa (fire rescue operations); the Texas Health and Human Services Commission (pharmacy benefit strategy); and the Minnesota Multistate Cooperative Purchasing Alliance (multi-jurisdictional pharmaceutical distribution). Representative opportunities include Seminole County's IFB60459723LAS for naloxone and drug deactivation systems (due July 26, 2023); the City of Tampa's IFB 26P00145 for medical and first aid supplies for the Fire Department Rescue Division, estimated at $700,000.00 with a 5% small local business enterprise discount and response deadline of March 13, 2026; Texas HHS's RFI HHS0017013 on direct-to-manufacturer pharmacy programs (response due April 3, 2026); and MMCAP's RFP S1070000015802 for generic pharmaceuticals and OTC products across multiple state and local members, with proposals due March 26, 2026. Geographic activity centers on Florida, Texas, and Minnesota, with multistate cooperative reach. The code shows limited recent relevant activity tied specifically to becanthone procurement.